Protara Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Protara Therapeutics, Inc. on June 8, 2022. The record date for the meeting was April 12, 2022, with 11,251,927 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Three proposals were submitted to a vote of security holders:
- Proposal 1: Election of Directors. Stockholders elected three Class II directors to serve until the 2025 Annual Meeting.
- Luke Beshar: 5,809,070 votes for, 798,989 withheld.
- Roger Garceau, M.D.: 6,281,362 votes for, 326,697 withheld.
- Gregory Sargen: 6,295,784 votes for, 312,275 withheld.
- Proposal 2: Ratification of Independent Auditor. Stockholders ratified the selection of Ernst and Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes For: 8,385,650
- Votes Against: 10,148
- Abstentions: 4,255
- Proposal 3: Advisory Vote on Executive Compensation. Stockholders approved the compensation of Named Executive Officers on an advisory basis.
- Votes For: 6,426,881
- Votes Against: 126,276
- Abstentions: 54,902
- Broker Non-Votes: 1,791,994
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that Ernst and Young LLP is the appointed auditor for the fiscal year ending December 31, 2022.
- Verification of the new Board composition, specifically the three Class II directors elected for terms ending in 2025.
- Review of the definitive proxy statement referenced in Proposal 3 for details on executive compensation.
- Assessment of the significant number of broker non-votes (1,791,994) relative to the total shares outstanding.